North America Dyspepsia Drug Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
|
 TCAC |
% |
| Principaux acteurs du marché |
>Marché des médicaments contre la dyspepsie en Amérique du Nord, par type (dyspepsie organique, dyspepsie non ulcéreuse, dyspepsie induite par les médicaments et autres), type de traitement (médicaments et chirurgie), type de médicament (de marque et générique), ordonnance (médicaments sans ordonnance et médicaments sur ordonnance), voie d'administration (orale et injectable), sexe (homme et femme), utilisateur final (hôpitaux, cliniques, établissements de soins à domicile, cliniques spécialisées, centres de chirurgie ambulatoire , instituts de recherche universitaires et gouvernementaux et autres), canal de distribution (appels d'offres directs et ventes au détail) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché des médicaments contre la dyspepsie en Amérique du Nord
Le marché nord-américain des médicaments contre la dyspepsie devrait croître au cours de la période de prévision en raison de la prévalence croissante de la dyspepsie et de l'adoption croissante de modes de vie malsains. Le marché est également influencé par l'augmentation de la prévalence des troubles métaboliques. Cependant, le marché nord-américain des médicaments contre la dyspepsie devrait être entravé par les effets secondaires possibles des médicaments utilisés pour la dyspepsie et la préférence croissante pour les remèdes naturels et à base de plantes. Le vieillissement de la population et l'augmentation du nombre de médicaments approuvés devraient constituer des opportunités de croissance du marché. Cependant, des réglementations strictes et un manque de sensibilisation à la dyspepsie au sein de la population devraient remettre en cause la croissance du marché.
Data Bridge Market Research analyse que le marché nord-américain des médicaments contre la dyspepsie devrait croître à un TCAC de 5,6 % au cours de la période de prévision de 2023 à 2030.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en milliers, volumes en unités et prix en USD |
|
Segments couverts |
Type (dyspepsie organique, dyspepsie non ulcéreuse, dyspepsie induite par des médicaments et autres), type de traitement (médicaments et chirurgie), type de médicament (de marque et générique), ordonnance (médicaments sans ordonnance et médicaments sur ordonnance), voie d'administration (orale et injectable), sexe (homme et femme), utilisateur final (hôpitaux, cliniques, établissements de soins à domicile, cliniques spécialisées, centres de chirurgie ambulatoire, instituts de recherche universitaires et gouvernementaux et autres), canal de distribution (ventes directes et au détail) |
|
Pays couverts |
États-Unis, Canada et Mexique |
|
Acteurs du marché couverts |
Bayer AG, Cadila Pharmaceuticals, Sanofi, Lupin, Abbott, Perrigo Company plc, AstraZeneca, Procter & Gamble et Reckitt Benckiser, entre autres. |
Définition du marché
Dyspepsia, commonly known as indigestion, is the pain and discomfort experienced in the abdomen after eating. It is usually a sign of an underlying condition like GERD (gastroesophageal reflux disease), gallbladder, and ulcer disease. Treatment for dyspepsia depends on the cause and severity. Treating an underlying condition or changing a person's medication will reduce dyspepsia. Dyspepsia is divided into 2 main categories: "organic" and "functional dyspepsia" (FD). Organic causes of dyspepsia are peptic ulcer, gastroesophageal reflux disease, gastric or esophageal cancer, pancreatic or biliary disorders, intolerance to food or drugs, and other infectious or systemic diseases. Functional dyspepsia (dis-PEP-see-uh) is a term for recurring symptoms of an upset stomach that have no obvious cause. Functional dyspepsia is also called non ulcer dyspepsia.
North America Dyspepsia Drug Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
DRIVERS
- Increasing prevalence of dyspepsia
Dyspepsia, commonly known as indigestion, is a gastrointestinal disorder that affects millions of people in North America. It is a condition that causes discomfort, pain, and a feeling of fullness or bloating in the upper abdomen. Dyspepsia can be caused by a variety of factors such as eating too quickly, consuming spicy or fatty foods, or as a side effect of medication.
The increasing prevalence of dyspepsia is one of the key driving factors for the growth of the dyspepsia drug market. The rising incidence of dyspepsia can be attributed to several factors such as changes in lifestyle, dietary habits, and an aging population. As people age, they are more susceptible to digestive problems, including dyspepsia. With the growing number of older adults, there is a higher demand for dyspepsia drugs.
In addition, different digestive diseases like irritable bowel syndrome, gastroparesis, gastritis, and peptic ulcer disease also cause dyspepsia, due to the increasing prevalence of the mentioned disease. Thus the growing prevalence of dyspepsia and other digestive disorders causing dyspepsia is expected to act as the driver for the market’s growth. The use of dyspepsia drugs for relieving the symptoms of dyspepsia and treating the dyspepsia has the potential to improve patient outcomes and reduce the burden of dyspepsia. Thus, the increasing prevalence of dyspepsia is driving the demand for dyspepsia drugs worldwide to increase the incidence and prevalence of the dyspepsia among population.
- Rise in the adoption of unhealthy lifestyle
In recent years, there has been a rise in the adoption of unhealthy lifestyles, which has contributed to an increase in the prevalence of dyspepsia. Unhealthy lifestyle choices such as a diet high in processed foods, lack of exercise, and excessive alcohol consumption can all contribute to dyspepsia.
As a result, there has been a corresponding increase in the demand for dyspepsia drugs, as people seek relief from their symptoms. The dyspepsia drug market has responded to this demand with a variety of medications, including proton pump inhibitors, H2 receptor antagonists, and antacids.
The rise in the adoption of unhealthy lifestyles can be attributed to several factors, including changes in dietary habits, increasing stress levels, and a sedentary lifestyle. Modern life is often characterized by long working hours, high levels of stress, and easy access to fast food and other unhealthy options. These factors can contribute to dyspepsia and other related conditions such as gastroesophageal reflux disease (GERD).
In conclusion, dyspepsia is a common condition that can be caused by a variety of factors, including unhealthy lifestyle choices. The rise in the adoption of unhealthy lifestyles has contributed to an increase in the prevalence of dyspepsia, and the demand for effective dyspepsia drugs has correspondingly increased which is expected to act as a driver for the growth of the market.
OPPORTUNITY
- Growing aging population
The number of people who are 65 and older is expected to reach 1.5 billion by the year 2050, according to estimates, which shows that the world's population is rapidly aging and growing older. People have a higher risk of developing chronic health conditions as they get older. This includes digestive disorders such as dyspepsia, which can occur as a result of aging.
There is a significant opportunity for the expansion of the dyspepsia drug market presented by the growing and aging population. Because more and more people are having problems with their digestive systems, there is a growing need for effective treatments that can reduce the severity of their symptoms and enhance their overall quality of life.
In addition, the treatment of dyspepsia may need to be tailored specifically to the requirements of an aging population. It is possible for older people to have multiple chronic conditions and to be taking multiple medications at the same time, both of which can increase the likelihood of negative drug interactions and side effects. As a result, there is a demand for dyspepsia medications that are both risk-free and effective when administered to older adults. And with aging people also lose their physical and immunity strength which leads to causing an increasing prevalence of several gastro-related diseases including dyspepsia.
Hence increase in the aging population causing dyspepsia and its symptoms and the people's preference for preventive healthcare is expected to act as an opportunity for the growth of the dyspepsia drug market.
RESTRAINT/CHALLENGE
- Lack of awareness about dyspepsia among the population
The shortage of skills is already impacting the nation, with an increasing number of people being forced to wait more than six months for their dental treatments. There is a shortage of skilled professionals in the field of Dyspepsia Drug in emerging or developing countries due to technical advancements, basic infrastructure, and several other factors.
The lack of skilled professionals is partly due to the rigorous education and training required to become a dental professional as well as the competitive job market. Moreover, skilled dentists need more formally-trained, licensed dental assistants to help maintain and increase access to oral healthcare to operate and execute advanced technological systems such as dyspepsia drug systems.
The emerging countries lack skilled professionals who cannot operate the new technologies effectively. This might create a challenge in the market for new technologies to emerge as these countries are delaying the onset of technologically driven advancements in the market.
Recent Developments
- In April 2023, Sanofi announced that it had completed the acquisition of Provention Bio, Inc. This acquisition has helped the company in the expansion of its business in general medicine.
- In July 2022, ANI Pharmaceuticals, Inc. announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, a privately owned biopharmaceutical company.
North America Dyspepsia Drug Market Segmentation
The North America dyspepsia drug market is segmented into type, treatment type, drug type, prescription, route of administration, gender, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Non-Ulcer Dyspepsia
- Organic Dyspepsia
- Drug Induced Dyspepsia
- Others
Based on type, North America dyspepsia drug market is segmented into organic dyspepsia, non-ulcer dyspepsia, drug induced dyspepsia, and others.
Treatment Type
- Medication
- Surgery
Based on treatment type, North America dyspepsia drug market is segmented into medication and surgery.
Drug Type
- Branded
- Generic
Based on drug type North America dyspepsia drug market is segmented into generic, and branded.
Prescription
- Without Prescription Drugs
- Prescription Drugs
Based on prescription, North America dyspepsia drug market is segmented into without prescription drugs and prescription drugs.
Route of Administration
- Oral
- Injectable
Based on the route of administration, North America dyspepsia drug market is segmented into oral, and injectable.
Gender
- Male
- Female
Based on gender, North America dyspepsia drug market is segmented into male and female.
End User
- Hospitals
- Clinics
- Homecare Settings
- Specialty Clinics
- Ambulatory Centers
- Academic and Government Research Institutes
- Others
En fonction de l’utilisateur final, le marché nord-américain des médicaments contre la dyspepsie est segmenté en hôpitaux, cliniques, établissements de soins à domicile, cliniques spécialisées, centres de chirurgie ambulatoire, instituts de recherche universitaires et gouvernementaux, et autres.
Canal de distribution
- Appel d'offres direct
- Ventes au détail
En fonction du canal de distribution, le marché nord-américain des médicaments contre la dyspepsie est segmenté en appels d’offres directs et ventes au détail.
Analyse/perspectives régionales du marché des médicaments contre la dyspepsie en Amérique du Nord
Le marché nord-américain des médicaments contre la dyspepsie est analysé et des informations et tendances sur la taille du marché sont fournies en fonction du type, du type de traitement, du type de médicament, de la prescription, de la voie d'administration, du sexe, de l'utilisateur final et du canal de distribution.
Les pays couverts dans ce rapport de marché sont les États-Unis, le Canada et le Mexique.
Les États-Unis devraient dominer le marché nord-américain des médicaments contre la dyspepsie en raison de l’augmentation des dépenses de santé et de la forte prévalence des troubles métaboliques observée dans le pays.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour chaque pays. En outre, la présence et la disponibilité des marques nord-américaines et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales et de l'impact des tarifs nationaux et des routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché des médicaments contre la dyspepsie en Amérique du Nord
Le paysage concurrentiel du marché nord-américain des médicaments contre la dyspepsie fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, la présence en Amérique du Nord, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché.
Certains des principaux acteurs du marché opérant sur le marché sont Bayer AG, Cadila Pharmaceuticals., Sanofi, Lupin., Abbott., Perrigo Company plc, AstraZeneca, Procter & Gamble et Reckitt Benckiser, entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA DYSPEPSIA DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END-USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA
7 INDUSTRY INSIGHTS:
8 NORTH AMERICA DYSPEPSIA DRUG MARKET, REGULATION
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASING PREVALENCE OF DYSPEPSIA
9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE
9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS
9.2 RESTRAINTS
9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA
9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES
9.3 OPPORTUNITIES
9.3.1 GROWING AGING POPULATION
9.3.2 RISE IN THE DRUG APPROVAL
9.4 CHALLENGES
9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION
9.4.2 STRINGENT REGULATIONS
10 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TYPE
10.1 OVERVIEW
10.2 NON-ULCER DYSPEPSIA
10.3 ORGANIC DYSPEPSIA
10.4 DRUG INDUCED DYSPEPSIA
10.5 OTHERS
11 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 DRUGS
11.2.1.1 ANTACIDS
11.2.1.1.1 PROTON PUMP INHIBITORS (PPI’S)
11.2.1.1.1.1 OMEPRAZOLE
11.2.1.1.1.2 LANSOPRAZOLE
11.2.1.1.1.3 ESOMEPRAZOLE
11.2.1.1.1.4 OTHERS
11.2.1.1.2 H2 BLOCKERS
11.2.1.1.2.1 CIMETIDINE
11.2.1.1.2.2 FAMOTIDINE
11.2.1.1.2.3 NIZATIDINE
11.2.1.1.2.4 RANITIDINE
11.2.1.1.2.5 OTHERS
11.2.1.2 GASTRIC PROKINETIC GENDERNTS
11.2.1.2.1 MOSAPRIDE CITRATE
11.2.1.2.2 METOCLOPRAMIDE
11.2.1.2.3 CISAPRIDE
11.2.1.2.4 ITOPRIDE HYDROCHLORIDE
11.2.1.2.5 DOMPERIDONE
11.2.1.2.6 OTHERS
11.2.1.3 ANTIBIOTICS
11.2.1.3.1 REFAXIMIN
11.2.1.3.2 AMOXICILLIN
11.2.1.3.3 CLARITHROMYCIN
11.2.1.3.4 METRONIDAZOLE
11.2.1.3.5 LEVOFLOXACIN
11.2.1.3.6 TETRACYCLINE
11.2.1.3.7 OTHERS
11.2.1.4 OTHERS
11.2.2 NON- DRUGS
11.2.2.1 PROBIOTICS
11.2.2.1.1 LACTOBACILLUS
11.2.2.1.2 BIFIDOBACTERIUM
11.2.2.1.3 BACILLUS
11.2.2.1.4 STREPTOCOCCUS
11.2.2.1.5 OTHERS
11.2.2.2 PREBIOTICS
11.3 SURGERY
12 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERIC
12.3 BRANDED
13 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION
13.1 OVERVIEW
13.2 WITHOUT PRESCRIPTION DRUGS
13.3 PRESCRIPTION DRUGS
14 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 TABLETS
14.2.2 CAPSULES
14.3 INJECTABLE
15 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY GENDER
15.1 OVERVIEW
15.2 FEMALE
15.2.1 30-50 YEARS
15.2.2 MORE THAN 50 YEARS
15.2.3 AGE LESS THAN 30
15.3 MALE
15.3.1 30-50 YEARS
15.3.2 MORE THAN 50 YEARS
15.3.3 AGE LESS THAN 30
16 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.2.1 TYPE
16.2.1.1 PUBLIC
16.2.1.2 PRIVATE
16.2.2 TIER
16.2.2.1 TIER 3
16.2.2.2 TIER 2
16.2.2.3 TEIR 1
16.3 CLINICS
16.4 HOMECARE SETTINGS
16.5 SPECIALTY CLINICS
16.6 AMBULATORY CENTERS
16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
16.8 OTHERS
17 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 RETAIL SALES
17.2.1 REATIL PHARMACY
17.2.2 HOSPITAL PHARMACY
17.2.3 ONLINE PHARMACY
17.3 DIRECT TENDER
18 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY REGION
18.1 NORTH AMERICA
18.1.1 U.S.
18.1.2 CANADA
18.1.3 MEXICO
19 NORTH AMERICA DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
20 SWOT ANALYSIS
21 NORTH AMERICA DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS
21.1 SANOFI
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENT
21.2 LUPIN
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 MANKIND PHARMA
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENT
21.4 ASTRAZENECA
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENT
21.5 BAYER AG
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENT
21.6 ABBOTT
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ANI PHARMACEUTICALS, INC.
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 AOSAIKANG PHARMACEUTICAL CO., LTD.
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 ASTERISK LABORATORIES (I) PVT. LTD
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENT
21.1 CADILA PHARMACEUTICALS
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 COMPANY SHARE ANALYSIS
21.10.4 PRODUCT PORTFOLIO
21.10.5 RECENT DEVELOPMENT
21.11 HANMI PHARM. CO., LTD.
21.11.1 COMPANY SNAPSHOT
21.11.2 REVENUE ANALYSIS
21.11.3 PRODUCT PORTFOLIO
21.11.4 RECENT DEVELOPMENT
21.12 MCNEIL CONSUMER PHARMACEUTICALS CO. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 OTSUKA PHARMACEUTICAL CO., LTD.
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 PERRIGO COMPANY PLC
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 PRESTIGE CONSUMER HEALTHCARE, INC.
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENT
21.16 PROCTER & GAMBLE
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENT
21.17 RECKITT BENCKISER.
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANALYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENT
21.18 REDHILL BIOPHARMA LTD
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENT
21.19 SALIX PHARMACEUTICALS OR ITS AFFILIATES (SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT DEVELOPMENT
21.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 WOODWARD PHARMA
21.21.1 COMPANY SNAPSHOT
21.21.2 PRODUCT PORTFOLIO
21.21.3 RECENT DEVELOPMENT
21.22 ZERIA PHARMACEUTICAL CO., LTD.
21.22.1 COMPANY SNAPSHOT
21.22.2 REVENUE ANALYSIS
21.22.3 PRODUCT PORTFOLIO
21.22.4 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
Liste des tableaux
TABLE 1 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 NORTH AMERICA NON-ULCER DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 3 NORTH AMERICA ORGANIC DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 4 NORTH AMERICA DRUG INDUCED DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 5 NORTH AMERICA OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 6 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 NORTH AMERICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 8 NORTH AMERICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 NORTH AMERICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 NORTH AMERICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 NORTH AMERICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 NORTH AMERICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 13 NORTH AMERICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 14 NORTH AMERICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 15 NORTH AMERICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 16 NORTH AMERICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 NORTH AMERICA SURGERY IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 18 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 19 NORTH AMERICA GENERIC IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 20 NORTH AMERICA BRANDED IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 21 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 22 NORTH AMERICA WITHOUT PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 23 NORTH AMERICA PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 24 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 25 NORTH AMERICA ORAL IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 26 NORTH AMERICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 27 NORTH AMERICA INJECTABLE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 28 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 29 NORTH AMERICA FEMALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 30 NORTH AMERICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 31 NORTH AMERICA MALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 32 NORTH AMERICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 33 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 34 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 35 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 36 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 37 NORTH AMERICA CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 38 NORTH AMERICA HOMECARE SETTINGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 39 NORTH AMERICA SPECIALTY CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 40 NORTH AMERICA AMBULATORY CENTERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 41 NORTH AMERICA ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 42 NORTH AMERICA OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 43 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 44 NORTH AMERICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 45 NORTH AMERICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 46 NORTH AMERICA DIRECT TENDER IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 47 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 48 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 NORTH AMERICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 51 NORTH AMERICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 52 NORTH AMERICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 53 NORTH AMERICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 NORTH AMERICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 55 NORTH AMERICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 NORTH AMERICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 57 NORTH AMERICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 58 NORTH AMERICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 59 NORTH AMERICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 NORTH AMERICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 61 NORTH AMERICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 NORTH AMERICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 NORTH AMERICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 64 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 65 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 66 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 67 NORTH AMERICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 68 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 69 NORTH AMERICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 70 NORTH AMERICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 71 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 72 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 73 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 74 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 75 NORTH AMERICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 76 U.S. DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 77 U.S. DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 78 U.S. MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 79 U.S. DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 U.S. ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 U.S. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 U.S. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 83 U.S. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 84 U.S. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 85 U.S. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 86 U.S. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 87 U.S. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 88 U.S. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 89 U.S. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 90 U.S. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 91 U.S. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 92 U.S. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 93 U.S. NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 94 U.S. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 95 U.S. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 96 U.S. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 97 U.S. DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 98 U.S. BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 99 U.S. DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 100 U.S. DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 101 U.S. ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 102 U.S. DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 103 U.S. FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 104 U.S. MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 105 U.S. DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 106 U.S. HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 107 U.S. HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 108 U.S. DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 109 U.S. RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 110 CANADA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 111 CANADA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 CANADA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 113 CANADA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 CANADA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 115 CANADA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 116 CANADA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 117 CANADA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 118 CANADA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 119 CANADA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 120 CANADA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 121 CANADA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 122 CANADA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 123 CANADA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 124 CANADA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 125 CANADA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 126 CANADA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 127 CANADA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 128 CANADA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 129 CANADA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 130 CANADA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 131 CANADA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 132 CANADA BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 133 CANADA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 134 CANADA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 135 CANADA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 136 CANADA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 137 CANADA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 138 CANADA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 139 CANADA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 140 CANADA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 141 CANADA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 142 CANADA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 143 CANADA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 144 MEXICO DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 MEXICO DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 146 MEXICO MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 147 MEXICO DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 148 MEXICO ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 149 MEXICO PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 150 MEXICO PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 151 MEXICO PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 152 MEXICO H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 153 MEXICO H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 154 MEXICO H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 155 MEXICO GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 156 MEXICO GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 157 MEXICO GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 158 MEXICO ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 159 MEXICO ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 160 MEXICO ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 161 MEXICO NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 162 MEXICO PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 163 MEXICO PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 164 MEXICO PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 165 MEXICO DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 166 MEXICO BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 167 MEXICO DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 168 MEXICO DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 169 MEXICO ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 170 MEXICO DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 171 MEXICO FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 172 MEXICO MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 173 MEXICO DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 174 MEXICO HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 175 MEXICO HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 176 MEXICO DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 177 MEXICO RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
Liste des figures
FIGURE 1 NORTH AMERICA DYSPEPSIA DRUG MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA DYSPEPSIA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA DYSPEPSIA DRUG MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA DYSPEPSIA DRUG MARKET: NORTH AMERICA VS. REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA DYSPEPSIA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA DYSPEPSIA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA DYSPEPSIA DRUG MARKET: MULTIVARIATE MODELLING
FIGURE 8 NORTH AMERICA DYSPEPSIA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA DYSPEPSIA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA DYSPEPSIA DRUG MARKET: MARKET END-USER COVERAGE GRID
FIGURE 11 NORTH AMERICA DYSPEPSIA DRUG MARKET: SEGMENTATION
FIGURE 12 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS IS EXPECTED TO DRIVE THE NORTH AMERICA DYSPEPSIA DRUG MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030
FIGURE 13 NON-ULCER DYSPEPSIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DYSPEPSIA DRUG MARKET IN 2023 & 2030
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA DYSPEPSIA DRUG MARKET
FIGURE 15 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE, 2022
FIGURE 16 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 17 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 18 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , 2022
FIGURE 20 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 21 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , CAGR (2023-2030)
FIGURE 22 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , LIFELINE CURVE
FIGURE 23 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2022
FIGURE 24 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)
FIGURE 25 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 26 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2022
FIGURE 28 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2023-2030 (USD THOUSAND)
FIGURE 29 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, CAGR (2023-2030)
FIGURE 30 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, LIFELINE CURVE
FIGURE 31 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 32 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)
FIGURE 33 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 34 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY GENDER, 2022
FIGURE 36 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY GENDER, 2023-2030 (USD THOUSAND)
FIGURE 37 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 38 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY END USER, 2022
FIGURE 40 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 41 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY END USER, CAGR (2023-2030)
FIGURE 42 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 44 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 45 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 46 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 NORTH AMERICA DYSPEPSIA DRUG MARKET: SNAPSHOT (2022)
FIGURE 48 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2022)
FIGURE 49 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2023 & 2030)
FIGURE 50 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2022 & 2030)
FIGURE 51 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE (2023-2030)
FIGURE 52 NORTH AMERICA DYSPEPSIA DRUG MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
